Ajinomoto Cambrooke, Inc.
Alison Trager is an experienced professional in the pharmaceutical and healthcare industries, currently serving as Sr. Territory Manager/National Accounts at Ajinomoto Cambrooke, Inc. since October 2013, with previous roles as Territory Manager/Sales Trainer and Territory Manager. Prior experience includes positions at Cangene Biopharma as an Oncology/Transplant Product Specialist, Strativa Pharmaceuticals as an Area Sales Representative, and Ther-Rx Corporation as a Specialty Sales Representative. Alison also held a role as a Specialty Sales Representative-Phoslo at Nabi Biopharmaceuticals and worked as a Dietitian at Robert Wood Johnson University Hospital from 2001 to 2005. Alison Trager holds a Master of Family and Consumer Sciences in Nutrition from Bowling Green State University and a Bachelor's degree in Nutrition Sciences from the University of Delaware.
This person is not in any teams
This person is not in any offices
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.